TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01578070

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.2μg Act-HIB®
Description: 0.2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ViscoGel® and 0.2μg Act-HIB®
Description: Pre-selected dose of ViscoGel® (from phase A) and Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ViscoGel® and 2μg Act-HIB®
Description: Pre-selected dose of ViscoGel® (from phase A) and 2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2μg Act-HIB®
Description: 2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 10μg Act-HIB®
Description: Clinical standard dose of 10μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
Study: NCT03358797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention-control
Description: Lifestyle intervention with presentations by multiple professionals (nutritionists, exercise trainers, and psychotherapists), this intervention will include Mediterranean diet education, physical activity, social support, food tasting and cooking, goal setting,and women's health topics

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community based intervention with resilience training
Description: Lifestyle intervention with presentations by multiple professionals (nutritionists, exercise trainers, and psychotherapists), this intervention will include Mediterranean diet education, physical activity, social support, food tasting and cooking, goal setting, and women's health topics. In addition, there will be content targeting resilience training including: positive emotions, cognitive flexibility, life meaning, and active coping strategies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intervention-HPP
Description: Lifestyle intervention with presentations by multiple professionals (nutritionists, exercise trainers, and psychotherapists), this intervention will include Mediterranean diet education, physical activity, social support, food tasting and cooking, goal setting,and women's health topics. In addition, there will be training in leadership skills, community interventions, community needs assessment, intervention planning and outcomes assessment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pilot
Description: Lifestyle intervention with presentations by multiple professionals (nutritionists, exercise trainers, and psychotherapists), this intervention will include Mediterranean diet education, physical activity, social support, food tasting and cooking, goal setting, and women's health topics. In addition, there will be content targeting resilience training including: positive emotions, cognitive flexibility, life meaning, and active coping strategies.
Study: NCT04569253

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TempSure
Description: Non-invasive radiofrequency treatments
Study: NCT05744908

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pentosan Polysulphate
Description: 300mg 3 times a day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pentosan Polysulphate
Description: 300mg 3 times a day
Study: NCT04141046

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XCSITE100 Stimulator - Individualized theta-tACS
Description: 20 second ramp-in and ramp-out with 40 minutes of stimulation for a total of 2440 seconds of stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XCSITE100 Stimulator - Individualized alpha-tACS
Description: 20 second ramp-in and ramp-out with 40 minutes of stimulation for a total of 2440 seconds of stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: XCSITE100 Stimulator - Active Sham
Description: 20 seconds of ramp-in to 40 seconds of 10 Hz tACS with a ramp out of 20 seconds for a total of 80 seconds of stimulation
Study: NCT04356742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg
Description: Dapagliflozin 10mg, orally, once daily, up to 24weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dapagliflozin Placebo, orally, once daily, up to 24weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evogliptin 5mg
Description: Evogliptin 5mg, orally, once daily for background therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Evogliptin 5mg
Description: Evogliptin 5mg, orally, once daily for background therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin≥1000mg
Description: Metformin≥1000mg, orally, daily for background therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin≥1000mg
Description: Metformin≥1000mg, orally, daily for background therapy
Study: NCT00304239

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Metvix-PDT
Description: Metvix 160 mg/g Cream was applied for 3 hours with occlusive dressing, and illumination with non-coherent red light using the Aktilite CL128 lamp, with a total light dose 37 Joule/square centimeter (J/cm²). All eligible lesions on the participant were treated twice with an interval of 1 week between treatments.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle-PDT
Description: Vehicle Cream was applied for 3 hours with occlusive dressing, and illumination with non-coherent red light using the Aktilite CL128 lamp, with a total light dose 37 J/cm². All eligible lesions on the participant were treated twice with an interval of 1 week between treatments.
Study: NCT02902068

Intervention type: DEVICE
Intervention: NICaS Bio Impedance
Description: Hemodynamic monitoring will be carried out using non invasive NICaS cardiac impedance by the use of two electrodes stickers which are pasted on the wrists for about 6 minutes.~Monitoring will be done with women lying down or sitting up half an hour preoperatively (in the woman's surgery waiting room) intraoperatively, and postoperatively in the PACU.~Preoperative data will be compared to intraoperative and postoperative data, and will be analyzed in order to evaluate the dynamic cardiac output changes in women undergoing cesarean sections.
Study: NCT04288752

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR101 Lubricating Intravaginal Ring
Description: VR101 Lubricating Intravaginal Ring is a personal lubrication device, for vaginal application, intended to moisturize and lubricate, to enhance the ease and comfort of intimate sexual activity, and supplement the body's natural lubrication.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Ring
Description: Sham rings are visually identical to VR101 Lubricating Intravaginal Rings, but no lubricating solution was added.
Study: NCT01807039

Intervention type: PROCEDURE
Intervention: hip fracture surgery
Description: we evaluate the relationship between the monitored parameters and 30 day survival
Study: NCT03939754

Intervention type: BEHAVIORAL
Intervention: Dedalo project
Description: Physical activity, healthy food, socialization and mental activity promotion
Study: NCT02759497

Intervention type: OTHER
Intervention: serum amyloid A level
Description: serum amyloid A level (SAA)
Study: NCT03189719

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-FU
Description: 800 mg/m\^2/day (4000 mg/m\^2 total per cycle) administered as continuous IV infusion on Days 1 to 5 (120 hours) of each 3-week cycle, or per local standard for 5-FU administration, up to 35 administrations.
Study: NCT03716973

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Density Programming
Description: Patients implanted with Medtronic spinal cord stimulator will have high density programming.
Study: NCT02734004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab
Study: NCT03098030

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dinutuximab
Description: Dinutuximab injection, for intravenous (IV) use

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dinutuximab
Description: Dinutuximab injection, for intravenous (IV) use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan injection, IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan injection, IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan injection, IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Topotecan for injection
Study: NCT03824652

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walnuts
Description: 2 ounces of walnuts daily for 4-10 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual diet
Description: Subject continues usual diet
Study: NCT00793702

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rdESAT-6 + rCFP-10
Description: rdESAT-6 + rCFP-10 skin test administered intradermally by the mantoux injection technique

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rdESAT-6 + rCFP-10
Description: rdESAT-6 + rCFP-10 skin test administered intradermally by the mantoux injection technique

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rdESAT-6 + rCFP-10
Description: rdESAT-6 + rCFP-10 skin test administered intradermally by the mantoux injection technique
Study: NCT00732524

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glipizide
Description: Glipizide XL 10 mg once daily 30 mins before breakfast

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glipizide and Glargine
Description: Glipizide XL 10 mg daily 30 minutes before breakfast Insulin Glargine 10 units subcutaneously at bedtime daily
Study: NCT03224078

Intervention type: OTHER
Intervention: data extraction
Description: No Special interventions except from data extraction form the respective routine data sources are planned .
Study: NCT02825576

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Sugammadex 2mg/kg given for reversal agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine/Glycopyrrolate
Description: Neostigmine 50 mcg/kg plus Glycopyrrolate 10 mcg/kg given for reversal agent
Study: NCT02122614

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR) plus PA monitoring and feedback from a pedometer
Description: Patients will enrol in a 12-week PR program comprising exercise training (3 times per week) and psychoeducation sessions (once a week). Patients will also receive a pedometer to self-monitor their PA during and after the PR program and individualized step-count goals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehabilitation (PR)
Description: Patients will enrol in a 12-week PR program comprising exercise training (3 times per week) and psychoeducation sessions (once a week).
Study: NCT01247792

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: SOPs for decision-making and communication
Description: Development and implementation of SOPs for timely and interdisciplinary EOL-decisionmaking and a communication strategy with relatives which addresses participants, set-up, time-points, and content
Study: NCT00267358

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RC-1291 HCl

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02926651

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Oral TXA (Tranexamic Acid)
Description: Three 650mg tablets of oral TXA 2 hours prior to incision with three 250mg tablets of ascorbic acid (oral TXA placebo) given 6 hours postoperatively and a final 750mg ascorbic acid dose given the morning of postoperative day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Oral TXA (Tranexamic Acid)
Description: Three 650mg tablets of oral TXA 2 hours prior to incision with three 250mg tablets of ascorbic acid (oral TXA placebo) given 6 hours postoperatively and a final 750mg ascorbic acid dose given the morning of postoperative day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multi-Dose Oral TXA (Tranexamic Acid)
Description: Three 650mg tablets of oral TXA 2 hours prior to incision with a second 1950mg oral TXA dose given 6 hours postoperatively and a final 1950mg oral TXA dose given the morning of postoperative day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multi-Dose Oral TXA (Tranexamic Acid)
Description: Three 650mg tablets of oral TXA 2 hours prior to incision with a second 1950mg oral TXA dose given 6 hours postoperatively and a final 1950mg oral TXA dose given the morning of postoperative day 1.
Study: NCT03964363

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unsupervised home-based physical prehabilitation
Description: Subsequent to screening and initial testing for frailty syndrome, participants receive an information booklet containing a selection of exercises, which allows independent prehabilitation at home.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unsupervised home-based physical prehabilitation
Description: Subsequent to screening and initial testing for frailty syndrome, participants receive an information booklet containing a selection of exercises, which allows independent prehabilitation at home.
Study: NCT04505826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OP-1250
Description: Complete Estrogen Receptor ANtagonist (CERAN)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OP-1250
Description: Complete Estrogen Receptor ANtagonist (CERAN)
Study: NCT02086344

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PBS
Description: TLH plus PBS
Study: NCT02086344

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TLH _adnexal preservation
Description: TLH without PBS
Study: NCT02423317

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation with Miller's blade
Description: Intubation is insertion of a hollow tube inside the trachea. It is done after laryngoscopy with Miller's blade.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubation with Airtraq
Description: Intubation is insertion of a hollow tube inside the trachea. It is done after laryngoscopy with Airtraq.
Study: NCT03722862

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low fiber
Description: Partially hydrolyzed guar gum (PHGG) commercially available as Sunfiber in 3 gram doses

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive the placebo/dextrose.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High fiber
Description: Partially hydrolyzed guar gum (PHGG) commercially available as Sunfiber in 6 gram doses
Study: NCT03698487

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention
Description: Pharmacist-led medication optimization intervention using an electronic tool (DBI Calculator©). The DBI Calculator is an electronic tool which calculates a score from the medication reconciliation list (medications taken prior to admission). It also creates a 'DBI report' which includes their full medication list, their DBI score, an explanation of the risks associated with their DBI score and highlighted medications which are contributing to their DBI score (that is, high risk medications which may be suitable for deprescribing).
Study: NCT01432028

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol and Progesterone
Description: 3 mg/day intranasal estradiol daily or 1,5 mg/day transdermal estradiol and 200 mg/day vaginal micronized progesterone for 14 days/month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol and Drospirenone
Description: oral estradiol 1mg and drospirenone 2 mg/day
Study: NCT00003404

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant Radiotherapy
Description: Adjuvant radiation therapy
Study: NCT01128868

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Proximal femur locking plate
Description: Proximal femur locking plate (PF-LCP, PF-LCP Hook Plate, Periloc)

Intervention type: DEVICE
Group type: OTHER
Intervention: Intertrochanteric nail
Description: Intertrochanteric nail (PFNA, TFN, GN)
Study: NCT02400463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Study: NCT00792207

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Coach software
Description: The intervention being tested, the Virtual Coach, is an automated empathic computer agent which will run on patient's home computer and engage the patient in dialogues to deliver personalized feedback, education and coaching based on physiological data.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Activity monitor and website
Description: The control group will use an activity monitor and a website to track activity levels.
Study: NCT01104571

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Trastuzumab 6mg/kg iv given on days 1 \& 8 pre-surgery \& one dose of 2mg/kg iv between days 15-19 post surgery

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Trastuzumab 6mg/kg iv given on days 1 \& 8 pre-surgery \& one dose of 2mg/kg iv between days 15-19 post surgery

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Trastuzumab 6mg/kg iv given on days 1 \& 8 pre-surgery \& one dose of 2mg/kg iv between days 15-19 post surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Part 1: Lapatinib 1500mg/day p.o. continuously for 28 days. Should start 11 days (+2 or -1 day) before the scheduled surgery.~Part 2: Lapatinib 1000mg/day p.o. continuously for 28 days. Should start 11 days (+2 or -1 day) before the scheduled surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Part 1: Lapatinib 1500mg/day p.o. continuously for 28 days. Should start 11 days (+2 or -1 day) before the scheduled surgery.~Part 2: Lapatinib 1000mg/day p.o. continuously for 28 days. Should start 11 days (+2 or -1 day) before the scheduled surgery.

Intervention type: OTHER
Group type: OTHER
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: OTHER
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study: NCT00547547

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high-selenium Brassica juncea
Description: Dose Level A: 3200 mcg orally day -7 through duration of treatment. Dose Level B: 4800 mcg orally day -7 through duration of treatment. Dose Level C: 6400 mcg orally day -7 through duration of treatment. Dose Level D: 7200 mcg orally day -7 through duration of treatment. Dose Level E: 8000 mcg orally day -7 through duration of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Dose Level 1: 750 mg/m2, 2x daily x 14 days every 21 days. Dose Level 1.5: 850 mg/m2, 2x daily x 14 days every 21 days. Dose Level 2: 1000 mg/m2, 2x daily x 14 days every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Dose Level 1: 100 mg/m2 on day 1 and day 8 every 21 days. Dose Level -1: 75 mg/m2 on day 1 and day 8 every 21 days.
Study: NCT02701699

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 18-F-FAZA
Description: All patients enrolled in this study will receive a FAZA PET Scan prior to their first radiation therapy fraction
Study: NCT02503410

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Subjects receive standard physical therapy, including outpatient visits as prescribed by the treating clinician and home-based exercises based on recommendations by the physical therapist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive gaming
Description: Subjects receive a combination of standard physical therapy in the clinic and home-based exercises that they perform using the Valedo system.
Study: NCT04206800

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ejaculatory abstinence less than 24 hours
Description: Males will have ejaculatory abstinence less than 24 hours before providing a semen sample the day of egg retrieval
Study: NCT03386474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brolucizumab 6 mg
Description: Administered as opthalmic solution for an intravitreal injection to the study eye

Intervention type: DRUG
Group type: OTHER
Intervention: Aflibercept 2 mg
Description: Administered as an opthalmic solution for intravitreal injection to the study eye
Study: NCT03051750

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complex Physical Therapy plus Pressotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Study: NCT03824652

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: usual diet
Description: Subject continues usual diet
Study: NCT03002389

Intervention type: DRUG
Group type: OTHER
Intervention: Anoro Ellipta
Description: inhaler approved by FDA (strength umeclidinium 65 microgram + vilanterol 25 microgram) One puff once a day for 30 days

Intervention type: DRUG
Group type: OTHER
Intervention: Arnuity Ellipta
Description: inhaler approved by FDA (strength 250 microgram) One puff twice a day for 30 days
Study: NCT03824652

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: phone counseling with dietitian
Description: Weekly calls with dietitian
Study: NCT04264442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losmapimod
Description: Patients will receive Losmapimod 15 mg by mouth twice daily for a total of 30 mg daily until 90 days after commercial drug is available post regulatory approval or until the study is discontinued by the Sponsor. The study drug should be taken with food and the date and time of each dose taken should be recorded in the subject diary.